Last Updated on November 11, 2024 by The Health Master
The United States Food & Drug Administration (USFDA) has completed a GMP inspection at Dr Reddy’s API manufacturing facility in Bollaram, Hyderabad (CTO-3).
The inspection was conducted from June 12, 2023 to June 16, 2023. The inspection closed with zero observations.
The inspection closed with zero observations
Additionally, the inspection conducted by the USFDA at company’s formulations manufacturing facility in Srikakulam (FTO SEZ PU2), the company has received the Establishment Inspection Report (EIR).
The Agency has classified the inspection as Voluntary Action Indicated (VAI) and concluded that the inspection is “closed” under 21 CFR 20.64(d)(3).
Understanding GMP, cGMP, and WHO-GMP
USFDA issues Form 483 with 11 observations IPCA Labs: Ratlam
USFDA issues Form 483 with 4 observations to Aurobindo Pharma
USFDA issues Form 483 with zero observations to Pharma MSMEs: Gujarat
USFDA issues Form 483 with 3 observation to Zydus, Ahmedabad
USFDA issues Form 483 with zero observation to Piramal
USFDA issues Form 483 with 10 observations to Lupin, Pithampur
PCI and IPA join hands to enhance quality of Pharmacy Education
USFDA issues Form 483 with 11 observations IPCA Labs: Ratlam
UP Govt Drafts Pharmaceutical Industry Policy 2023: Details
CDSCO implements transparent reporting system for Cough Syrup exports
Safe Disposal of Unused Drugs: Urgent Need a Comprehensive Policy
PLI Schemes Drive Rs. 21,861 crore in investments for Pharmaceuticals and Medical Devices
Drug alert: 28 out of 1302 samples declared as NSQ in May 2023
Action to be taken against Pharmacies offering abnormal discounts: Karnataka
NPPA Guidelines: For change of Manufacturer in Notified Drug Formulations
